Advertisement

Topics

PubMed Journals Articles About "Methylphenidate And Parkinson's Disease" RSS

14:04 EDT 22nd May 2018 | BioPortfolio

Methylphenidate And Parkinson's Disease PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Methylphenidate And Parkinson's Disease articles that have been published worldwide.

More Information about "Methylphenidate And Parkinson's Disease" on BioPortfolio

We have published hundreds of Methylphenidate And Parkinson's Disease news stories on BioPortfolio along with dozens of Methylphenidate And Parkinson's Disease Clinical Trials and PubMed Articles about Methylphenidate And Parkinson's Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Methylphenidate And Parkinson's Disease Companies in our database. You can also find out about relevant Methylphenidate And Parkinson's Disease Drugs and Medications on this site too.

Showing "Methylphenidate Parkinson Disease" PubMed Articles 1–25 of 22,000+

Mild Cognitive Impairment in Parkinson's Disease-What Is It?

Mild cognitive impairment is a common feature of Parkinson's disease, even at the earliest disease stages, but there is variation in the nature and severity of cognitive involvement and in the risk of conversion to Parkinson's disease dementia. This review aims to summarise current understanding of mild cognitive impairment in Parkinson's disease. We consider the presentation, rate of conversion to dementia, underlying pathophysiology and potential biomarkers of mild cognitive impairment in Parkinson's dise...


Diabetes mellitus and Parkinson disease.

To investigate whether diabetes mellitus is associated with Parkinson-like pathology in people without Parkinson disease and to evaluate the effect of diabetes mellitus on markers of Parkinson pathology and clinical progression in drug-naive patients with early-stage Parkinson disease.

Motivators and Barriers to Exercise in Parkinson's Disease.

Despite evidence for the benefits of exercise in Parkinson's disease (PD), many patients remain sedentary for undefined reasons.


Ophthalmic disorders as a manifestation of Parkinson's disease.

Parkinson's disease is a severe neurodegenerative disease accompanied with the degeneration of dopaminergic neurons in the central and peripheral nervous system. The diagnosis of Parkinson's disease can still be made only on the stage of irreversible and nearly total degeneration of the nigrostriatum dopaminergic system and exhaustion of brain compensatory mechanisms that explains the low efficacy of therapy. Ophthalmic pathology is one of the nonmotor symptoms of Parkinson's disease. This can be explained ...

Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.

Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson's disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex.

Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.

Domperidone is a proposed treatment of orthostatic hypotension (OH) in Parkinson's disease (PD). However, domperidone use in PD is tempered by concerns regarding QT prolongation and ventricular tachyarrhythmia and sudden cardiac death (VT/SCD).

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

Multiple disease processes are associated with cognitive impairment in Parkinson disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer disease. It remains unknown whether tau pathology relates to cognition in patients with PD without dementia.

Constipation is not associated with DAT dopaminergic pathology in early de novo patients with Parkinson's disease.

Constipation is a common non-motor symptom of Parkinson's disease. Deposition of α-synuclein inclusions that spread from the gut to the substantia nigra through the vagus nerve has been recently speculated as a pre-motor and early stage of Parkinson's disease.

Average annual cost of Parkinson's disease in São Paulo, Brazil, with a focus on disease-related motor symptoms.

Although Parkinson's disease is the second most prevalent neurodegenerative disease worldwide, its cost in Brazil - South America's largest country - is unknown.

King's Parkinson's Disease Pain Scale for Assessment of Pain Relief Following Deep Brain Stimulation for Parkinson's Disease.

Pain is a prevalent and debilitating nonmotor symptom of Parkinson's disease (PD) that is often inadequately managed. Deep brain stimulation (DBS) has been shown to relieve pain in PD but an effective method of identifying which types of PD pain respond to DBS has not been established. We examine the effects of DBS on different types of PD pain using the King's Parkinson's disease pain scale (KPDPS), the only validated scale of PD pain.

Update in therapeutic strategies for Parkinson's disease.

To review recent advances in therapeutics for motor and nonmotor symptoms of Parkinson's disease.

Mifepristone reduces hypothalamo-pituitary-adrenal axis activation and restores weight loss in rats subjected to dietary restriction and methylphenidate administration.

This study evaluates the efficacy of mifepristone on weight restoration in rats subjected to dietary restriction and methylphenidate administration. 25 female rats aged between 9 and 12 months were divided into 2 groups: 5 controls (exposed only to dietary restriction) and 20 rats that were administered 5 mg/kg/d of methylphenidate before meal exposure, for 36 days. Among rats who responded to methylphenidate (weight loss of 15-25%) weeks after its administration, a group of 6 rats continued to receive on...

Comorbid Conditions in Parkinson's Disease: A Population-Based Study of Statewide Parkinson's Disease Registry.

In 1996, Nebraska became the first state in the United States to establish a Parkinson's disease (PD) Registry. The objectives of this study were to determine the most common comorbid conditions among PD patients receiving inpatient and outpatient services in Nebraska between 2004 and 2012, and to examine whether PD patients had increased risks of these conditions.

A Novel Animal Model of Parkinson's Disease Using Optogenetics: Representation of Various Disease Stages by Modulating the Illumination Parameter.

The classic animal model of Parkinson's disease (PD) using neurotoxin can only simulate fixed stages of the disease by causing irreversible damage to the nigrostriatal system.

Diminished EEG habituation to novel events effectively classifies Parkinson's patients.

We aimed to test if EEG responses to novel events reliably dissociated individuals with Parkinson's disease and controls, and if this dissociation was sensitive and specific enough to be a candidate biomarker of cognitive dysfunction in Parkinson's disease.

An assessment of Movement Disorder Society Task Force Diagnostic Criteria for Mild Cognitive Impairment in Parkinson's Disease.

Cognitive impairment is one of the most disabling non-motor symptoms of Parkinson disease (PD). Mild cognitive impairment (MCI) constitutes a major risk for the development of Parkinson's disease Dementia in the course of the disease. A Movement Disorder Society (MDS) Task Force proposed diagnostic criteria for mild cognitive impairment in Parkinson's disease (PD-MCI), comprising two operational levels: Level I and Level II.

Historical and cross-cultural perspectives on Parkinson's disease.

Parkinson's disease (PD) is a common neurodegenerative disorder, affecting up to 10 million people worldwide according to the Parkinson's Disease Foundation. Epidemiological and genetic studies show a preponderance of idiopathic cases and a subset linked to genetic polymorphisms of a familial nature. Traditional Chinese medicine and Ayurveda recognized and treated the illness that Western Medicine terms PD millennia ago, and descriptions of Parkinson's symptomatology by Europeans date back 2000 years to the...

Arytenoid cartilage movements are hypokinetic in Parkinson's disease: A quantitative dynamic computerised tomographic study.

Voice change is one of the earliest features of Parkinson's disease. However, quantitative studies of vocal fold dynamics which are needed to provide insight into disease biology, aid diagnosis, or track progression, are few.

Does Parkinson's disease start in the gut?

Current understanding of the pathophysiology of Parkinson's disease suggests a key role of the accumulation of alpha-synuclein in the pathogenesis. This critical review highlights major landmarks, hypotheses and controversies about the origin and progression of synucleinopathy in Parkinson's disease, leading to an updated review of evidence suggesting the enteric nervous system might be the starting point for the whole process. Although accumulating and compelling evidence favors this theory, the remaining ...

Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.

Gastrointestinal symptoms are common in Parkinson's disease and frequently precede the development of motor impairments. Intestinal inflammation has been proposed as a driver of disease pathology, and evaluation of inflammatory mediators in stool could possibly identify valuable early-stage biomarkers. We measured immune- and angiogenesis-related proteins in human stool to examine inflammatory profiles associated with Parkinson's disease.

Is acupuncture an alternative for the treatment of Parkinson’s Disease?

It has been proposed that acupuncture has several benefits for patients with Parkinson’s disease. However, its real clinical effect is still under discussion.

Degradation of Neuronal Encoding of Speech in the Subthalamic Nucleus in Parkinson's Disease.

Most of the patients with Parkinson's disease suffer from speech disorders characterized mainly by dysarthria and hypophonia.

Depression in Parkinson's disease: A case-control study.

To evaluate the association between Parkinson's disease (PD) prognosis and the patient's onset of depression.

Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson's disease or merely an inconsistent, age-dependent imaging finding?

Visualisation of nigrosome 1, a substructure of the healthy substantia nigra, was restricted in susceptibility weighted MR imaging in almost all patients with Parkinson's disease studied so far. The purpose of this study was to determine the degree of visibility of this substructure in subjects without Parkinson's disease and to examine the potential link between increasing brain iron accumulation with age and its detectability.

Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study.

We previously reported gut dysbiosis in patients with Parkinson's disease (PD).


Advertisement
Quick Search
Advertisement
Advertisement